Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $365.40.
Several research firms have issued reports on KRYS. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price on the stock.
View Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Price Performance
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. As a group, analysts anticipate that Krystal Biotech will post 7.68 earnings per share for the current year.
Insider Activity
In related news, Director Dino A. Rossi sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock valued at $16,278,020 in the last ninety days. 13.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Handelsbanken Fonder AB grew its stake in shares of Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares during the period. Fisher Asset Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $933,000. Principal Financial Group Inc. raised its stake in Krystal Biotech by 15.6% during the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock worth $40,697,000 after acquiring an additional 22,231 shares during the period. William Blair Investment Management LLC raised its stake in Krystal Biotech by 152.1% during the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after acquiring an additional 227,038 shares during the period. Finally, Biondo Investment Advisors LLC lifted its holdings in Krystal Biotech by 31.3% during the fourth quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock valued at $16,797,000 after purchasing an additional 16,245 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Stories
- Five stocks we like better than Krystal Biotech
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
